{
  "protocol": {
    "name": "Testosterone Replacement Therapy (TRT) - Standard Protocol",
    "version": "1.0",
    "therapy_type": "testosterone",
    "condition_treated": "Male Hypogonadism / Low Testosterone",
    "evidence_level": "clinical_practice",
    "overview": "Evidence-based testosterone replacement therapy protocol for adult males with clinically confirmed hypogonadism. Follows Endocrine Society Clinical Practice Guidelines for diagnosis, treatment initiation, monitoring, and dose optimization.",
    "duration_weeks": 24,
    "total_sessions": 10,
    "evidence_sources": [
      "Endocrine Society Clinical Practice Guidelines (2018)",
      "American Urological Association Guidelines",
      "Bhasin S, et al. J Clin Endocrinol Metab. 2018"
    ]
  },
  "steps": [
    {
      "sequence_order": 1,
      "step_type": "screening",
      "title": "Initial Endocrine Evaluation",
      "description": "Comprehensive evaluation including symptom assessment, medical history, physical examination, and initial laboratory testing to confirm diagnosis of hypogonadism.",
      "duration_minutes": 60,
      "required_roles": ["endocrinologist", "urologist", "primary_care"],
      "clinical_scales": ["ADAM Questionnaire", "AMS Score"],
      "vitals_monitoring": {
        "required": ["blood_pressure", "heart_rate", "weight", "height", "bmi"]
      },
      "documentation_requirements": {
        "symptoms": ["fatigue", "decreased_libido", "erectile_dysfunction", "mood_changes", "decreased_muscle_mass"],
        "medical_history": ["cardiovascular_disease", "diabetes", "sleep_apnea", "prostate_history"],
        "medications": ["current_medications", "supplements"]
      }
    },
    {
      "sequence_order": 2,
      "step_type": "screening",
      "title": "Baseline Laboratory Testing",
      "description": "Comprehensive hormone panel and safety labs obtained in morning (7-11 AM) to confirm diagnosis and establish baseline values.",
      "duration_minutes": 30,
      "required_roles": ["phlebotomist", "lab_technician"],
      "lab_tests_required": [
        "Total Testosterone (repeat if low)",
        "Free Testosterone",
        "Sex Hormone Binding Globulin (SHBG)",
        "Luteinizing Hormone (LH)",
        "Follicle Stimulating Hormone (FSH)",
        "Estradiol (E2)",
        "Prostate Specific Antigen (PSA)",
        "Complete Blood Count (CBC)",
        "Comprehensive Metabolic Panel (CMP)",
        "Lipid Panel",
        "Hemoglobin A1c"
      ],
      "diagnostic_criteria": {
        "testosterone_threshold": "< 300 ng/dL on two separate morning measurements",
        "symptoms_required": true
      }
    },
    {
      "sequence_order": 3,
      "step_type": "decision_point",
      "title": "Safety Check & Contraindication Review",
      "description": "Evaluate absolute and relative contraindications before treatment initiation.",
      "duration_minutes": 20,
      "required_roles": ["endocrinologist", "urologist"],
      "evaluation_rules": {
        "type": "safety_assessment",
        "absolute_contraindications": [
          {
            "condition": "prostate_cancer",
            "description": "Active or history of prostate cancer",
            "action": "exclude_from_treatment"
          },
          {
            "condition": "breast_cancer",
            "description": "Active or history of male breast cancer",
            "action": "exclude_from_treatment"
          },
          {
            "condition": "severe_heart_failure",
            "description": "NYHA Class IV heart failure",
            "action": "exclude_from_treatment"
          },
          {
            "condition": "hematocrit_high",
            "threshold": "> 54%",
            "action": "defer_until_resolved"
          }
        ],
        "relative_contraindications": [
          {
            "condition": "sleep_apnea_untreated",
            "description": "Untreated obstructive sleep apnea",
            "action": "require_treatment_first"
          },
          {
            "condition": "bph_severe",
            "description": "Severe benign prostatic hyperplasia with urinary symptoms",
            "action": "optimize_before_treatment"
          },
          {
            "condition": "psa_elevated",
            "threshold": "> 4.0 ng/mL or > 3.0 ng/mL with high risk",
            "action": "urology_evaluation_required"
          }
        ]
      },
      "branch_outcomes": [
        {
          "outcome_id": "cleared_for_treatment",
          "next_step": 4,
          "description": "No contraindications identified, proceed to treatment modality selection"
        },
        {
          "outcome_id": "defer_treatment",
          "next_step": "exit_protocol",
          "description": "Absolute contraindication present, patient not candidate for TRT"
        },
        {
          "outcome_id": "conditional_clearance",
          "next_step": 4,
          "description": "Relative contraindications addressed, proceed with enhanced monitoring"
        }
      ]
    },
    {
      "sequence_order": 4,
      "step_type": "decision_point",
      "title": "Treatment Modality Selection",
      "description": "Select optimal testosterone delivery method based on patient preference, lifestyle, cost, and clinical factors.",
      "duration_minutes": 30,
      "required_roles": ["endocrinologist", "urologist"],
      "evaluation_rules": {
        "type": "multi_factor_decision",
        "factors": [
          {
            "factor": "patient_preference",
            "options": ["injectable", "topical", "pellet", "oral"]
          },
          {
            "factor": "cost_considerations",
            "weight": "medium"
          },
          {
            "factor": "compliance_likelihood",
            "weight": "high"
          },
          {
            "factor": "hematocrit_baseline",
            "consideration": "If elevated, prefer topical to minimize erythrocytosis risk"
          }
        ],
        "modality_options": [
          {
            "modality": "intramuscular_injection",
            "description": "Testosterone cypionate or enanthate IM",
            "frequency": "Weekly or bi-weekly",
            "pros": ["Cost-effective", "Reliable absorption", "Stable levels with weekly dosing"],
            "cons": ["Injection required", "Potential peak/trough fluctuations with bi-weekly"],
            "typical_dose": "100-200 mg weekly or 200 mg bi-weekly"
          },
          {
            "modality": "subcutaneous_injection",
            "description": "Testosterone cypionate or enanthate SubQ",
            "frequency": "2-3 times weekly",
            "pros": ["Stable levels", "Smaller needles", "Self-administered"],
            "cons": ["More frequent injections", "Some insurance coverage issues"],
            "typical_dose": "50-80 mg 2-3 times weekly"
          },
          {
            "modality": "topical_gel",
            "description": "Transdermal testosterone gel 1-2%",
            "frequency": "Daily application",
            "pros": ["Non-invasive", "Steady levels", "Flexible dosing"],
            "cons": ["Daily compliance required", "Transfer risk", "More expensive"],
            "typical_dose": "50-100 mg daily"
          },
          {
            "modality": "pellet_implant",
            "description": "Subcutaneous testosterone pellets",
            "frequency": "Every 3-6 months",
            "pros": ["Infrequent dosing", "Excellent compliance", "Stable levels"],
            "cons": ["Minor surgical procedure", "Expensive", "Difficult dose adjustment"],
            "typical_dose": "800-1200 mg every 3-6 months"
          }
        ]
      },
      "branch_outcomes": [
        {
          "outcome_id": "injectable_selected",
          "next_step": 5
        },
        {
          "outcome_id": "topical_selected",
          "next_step": 5
        },
        {
          "outcome_id": "pellet_selected",
          "next_step": 5
        }
      ]
    },
    {
      "sequence_order": 5,
      "step_type": "decision_point",
      "title": "Initial Dose Determination",
      "description": "Calculate individualized starting dose based on patient factors, baseline testosterone level, and selected modality.",
      "duration_minutes": 15,
      "required_roles": ["endocrinologist", "urologist"],
      "evaluation_rules": {
        "type": "dose_calculation",
        "factors": [
          {
            "factor": "baseline_testosterone",
            "ranges": [
              {"min": 0, "max": 150, "severity": "severe", "dose_adjustment": "standard_dose"},
              {"min": 150, "max": 264, "severity": "moderate", "dose_adjustment": "standard_dose"},
              {"min": 264, "max": 300, "severity": "mild", "dose_adjustment": "lower_dose"}
            ]
          },
          {
            "factor": "age",
            "consideration": "Older patients (>65) may start at lower doses"
          },
          {
            "factor": "body_weight",
            "consideration": "Higher body weight may require higher doses"
          },
          {
            "factor": "shbg_level",
            "consideration": "High SHBG may require higher doses to achieve adequate free T"
          }
        ],
        "dosing_recommendations": {
          "injectable_im_weekly": {
            "standard": "100 mg weekly",
            "range": "80-200 mg weekly"
          },
          "injectable_subq": {
            "standard": "50 mg 2x weekly or 35 mg 3x weekly",
            "range": "40-80 mg per injection"
          },
          "topical_gel": {
            "standard": "50 mg daily (one pump)",
            "range": "25-100 mg daily"
          },
          "pellet": {
            "standard": "900-1000 mg every 4 months",
            "range": "800-1200 mg"
          }
        }
      },
      "branch_outcomes": [
        {
          "outcome_id": "standard_dose",
          "next_step": 6
        },
        {
          "outcome_id": "adjusted_dose",
          "next_step": 6
        }
      ]
    },
    {
      "sequence_order": 6,
      "step_type": "preparation",
      "title": "Treatment Initiation & Patient Education",
      "description": "Administer or prescribe initial treatment dose and provide comprehensive patient education on administration, monitoring, and potential side effects.",
      "duration_minutes": 45,
      "required_roles": ["endocrinologist", "urologist", "nurse", "pharmacist"],
      "education_topics": [
        "How to self-administer injections (if applicable)",
        "Proper application technique for gels (if applicable)",
        "Expected timeline for symptom improvement (4-12 weeks)",
        "Potential side effects and when to report",
        "Importance of follow-up labs and appointments",
        "Contraception counseling (TRT causes infertility)",
        "Avoiding transfer of topical products to partners/children",
        "Signs of adverse effects (chest pain, leg swelling, breathing difficulty)"
      ],
      "monitoring_plan": {
        "symptom_tracking": "Patient to log symptoms weekly",
        "adverse_events": "Report immediately: chest pain, dyspnea, leg swelling, urinary retention",
        "next_labs": "6 weeks post-initiation"
      }
    },
    {
      "sequence_order": 7,
      "step_type": "followup",
      "title": "Early Follow-up Check (Week 2-4)",
      "description": "Early phone or in-person check to assess tolerance, compliance, and any immediate concerns.",
      "duration_minutes": 15,
      "required_roles": ["nurse", "medical_assistant"],
      "assessment_points": [
        "Treatment compliance",
        "Any injection site reactions or skin irritation",
        "Early adverse effects",
        "Questions or concerns",
        "Reinforcement of administration technique"
      ]
    },
    {
      "sequence_order": 8,
      "step_type": "followup",
      "title": "Six-Week Labs & Clinical Assessment",
      "description": "First comprehensive follow-up with labs to assess testosterone levels, safety parameters, and early response.",
      "duration_minutes": 30,
      "required_roles": ["endocrinologist", "urologist"],
      "lab_tests_required": [
        "Total Testosterone (trough for injectables, steady-state for topicals)",
        "Free Testosterone",
        "Estradiol",
        "Complete Blood Count (CBC) - especially hematocrit",
        "Comprehensive Metabolic Panel",
        "PSA"
      ],
      "clinical_assessment": [
        "Symptom improvement (energy, libido, mood)",
        "Physical examination",
        "Adverse effects screening",
        "Compliance assessment"
      ],
      "vitals_monitoring": {
        "required": ["blood_pressure", "heart_rate", "weight"]
      },
      "target_levels": {
        "total_testosterone": "500-900 ng/dL (mid-normal range)",
        "free_testosterone": "Within normal range",
        "estradiol": "< 50 pg/mL (some patients may need AI if elevated)",
        "hematocrit": "< 52%",
        "psa": "< 4.0 ng/mL and not rising rapidly"
      }
    },
    {
      "sequence_order": 9,
      "step_type": "decision_point",
      "title": "Dose Optimization Decision",
      "description": "Evaluate lab results and clinical response to determine if dose adjustment is needed.",
      "duration_minutes": 20,
      "required_roles": ["endocrinologist", "urologist"],
      "evaluation_rules": {
        "type": "dose_adjustment",
        "conditions": [
          {
            "condition": "testosterone_low",
            "criteria": "Total T < 500 ng/dL",
            "action": "increase_dose",
            "adjustment": "Increase by 20-25%"
          },
          {
            "condition": "testosterone_high",
            "criteria": "Total T > 1000 ng/dL or free T elevated",
            "action": "decrease_dose",
            "adjustment": "Decrease by 20-25%"
          },
          {
            "condition": "testosterone_optimal",
            "criteria": "Total T 500-900 ng/dL, symptoms improving",
            "action": "continue_current_dose"
          },
          {
            "condition": "hematocrit_elevated",
            "criteria": "Hct 52-54%",
            "action": "decrease_dose_or_phlebotomy",
            "note": "Consider therapeutic phlebotomy if T levels optimal"
          },
          {
            "condition": "hematocrit_high",
            "criteria": "Hct > 54%",
            "action": "hold_treatment",
            "note": "Hold TRT until Hct < 52%, then restart at lower dose"
          },
          {
            "condition": "estradiol_high",
            "criteria": "E2 > 50 pg/mL with symptoms (gynecomastia, water retention)",
            "action": "consider_aromatase_inhibitor",
            "options": ["Decrease dose", "Add low-dose anastrozole 0.25-0.5 mg twice weekly"]
          }
        ],
        "decision_matrix": {
          "low_T_good_response": "Increase dose to optimize levels",
          "optimal_T_good_response": "Continue current regimen",
          "optimal_T_poor_response": "Consider other causes, specialty referral",
          "high_T_any_response": "Decrease dose",
          "elevated_hematocrit": "Phlebotomy or dose reduction",
          "high_hematocrit": "Hold treatment temporarily"
        }
      },
      "branch_outcomes": [
        {
          "outcome_id": "increase_dose",
          "next_step": 10,
          "description": "Increase dose, repeat labs in 6 weeks"
        },
        {
          "outcome_id": "decrease_dose",
          "next_step": 10,
          "description": "Decrease dose, repeat labs in 6 weeks"
        },
        {
          "outcome_id": "continue_dose",
          "next_step": 10,
          "description": "Continue current dose, proceed to maintenance monitoring"
        },
        {
          "outcome_id": "hold_treatment",
          "next_step": "specialty_management",
          "description": "Hold TRT, address safety concern, reassess for restart"
        }
      ]
    },
    {
      "sequence_order": 10,
      "step_type": "followup",
      "title": "Three-Month Follow-up & Optimization",
      "description": "Comprehensive follow-up after dose adjustments to confirm optimal levels and clinical response.",
      "duration_minutes": 30,
      "required_roles": ["endocrinologist", "urologist"],
      "lab_tests_required": [
        "Total Testosterone",
        "Free Testosterone",
        "Estradiol",
        "CBC (hematocrit)",
        "CMP",
        "PSA",
        "Lipid Panel"
      ],
      "clinical_assessment": [
        "Symptom resolution assessment",
        "Physical examination including DRE (if indicated)",
        "Quality of life assessment",
        "Adverse effects monitoring",
        "Compliance and satisfaction"
      ],
      "goals": {
        "primary": "Testosterone levels in target range (500-900 ng/dL)",
        "secondary": [
          "Symptom improvement or resolution",
          "No significant adverse effects",
          "Hematocrit < 52%",
          "Stable PSA",
          "Good treatment adherence"
        ]
      }
    }
  ],
  "ongoing_monitoring": {
    "first_year": {
      "frequency": "Every 3-6 months",
      "labs": ["Total T", "CBC", "PSA", "CMP"],
      "clinical": "Symptom assessment, physical exam, adverse effects"
    },
    "after_first_year": {
      "frequency": "Every 6-12 months (if stable)",
      "labs": ["Total T", "CBC", "PSA", "CMP", "Lipids annually"],
      "clinical": "Symptom maintenance, DRE annually if age-appropriate, bone density if indicated"
    }
  },
  "safety_monitoring": {
    "absolute_contraindications": [
      "Prostate cancer (active or history)",
      "Breast cancer (active or history)",
      "Severe heart failure (NYHA Class IV)",
      "Hematocrit > 54%",
      "Severe untreated obstructive sleep apnea"
    ],
    "adverse_effects_to_monitor": [
      {
        "effect": "Erythrocytosis",
        "monitoring": "CBC with differential every 3-6 months",
        "management": "Dose reduction, therapeutic phlebotomy, or treatment discontinuation if Hct > 54%"
      },
      {
        "effect": "Prostate effects",
        "monitoring": "PSA and DRE at baseline and regularly",
        "management": "Urology referral if PSA increases > 1.4 ng/mL in 12 months or > 0.4 ng/mL annually"
      },
      {
        "effect": "Gynecomastia",
        "monitoring": "Clinical breast exam",
        "management": "Check estradiol, consider aromatase inhibitor or dose adjustment"
      },
      {
        "effect": "Sleep apnea worsening",
        "monitoring": "Sleep quality assessment at each visit",
        "management": "Sleep study if symptoms worsen, optimize CPAP compliance"
      },
      {
        "effect": "Cardiovascular events",
        "monitoring": "Blood pressure, cardiovascular symptoms",
        "management": "Risk factor optimization, cardiology referral if needed"
      },
      {
        "effect": "Liver toxicity",
        "monitoring": "CMP with liver function tests",
        "management": "Dose adjustment or discontinuation if LFTs elevated"
      },
      {
        "effect": "Fluid retention",
        "monitoring": "Weight, edema assessment",
        "management": "Sodium restriction, dose adjustment if significant"
      },
      {
        "effect": "Acne/oily skin",
        "monitoring": "Skin assessment",
        "management": "Dermatology referral if severe, dose optimization"
      },
      {
        "effect": "Testicular atrophy",
        "monitoring": "Physical examination",
        "management": "Expected with TRT; if fertility desired, consider hCG co-treatment"
      },
      {
        "effect": "Mood changes",
        "monitoring": "Depression/anxiety screening",
        "management": "Dose adjustment, mental health referral if needed"
      }
    ]
  },
  "special_populations": {
    "elderly_patients": {
      "considerations": [
        "Start at lower doses",
        "More gradual titration",
        "Enhanced cardiovascular monitoring",
        "More frequent PSA monitoring",
        "Greater risk of polycythemia"
      ]
    },
    "patients_with_cardiovascular_disease": {
      "considerations": [
        "Cardiology clearance may be needed",
        "Start at lower doses",
        "Close monitoring of blood pressure and symptoms",
        "Hematocrit monitoring critical",
        "Consider risks vs. benefits carefully"
      ]
    },
    "fertility_preservation": {
      "considerations": [
        "TRT causes suppression of spermatogenesis",
        "Offer sperm banking before treatment",
        "Consider hCG monotherapy or hCG + FSH if fertility desired",
        "Regular counseling about contraception needs during TRT"
      ]
    }
  },
  "discontinuation_criteria": [
    "Patient request",
    "Persistent hematocrit > 54% despite interventions",
    "Prostate cancer diagnosis",
    "Severe cardiovascular event potentially related to TRT",
    "Intolerable side effects not manageable with dose adjustment",
    "Non-compliance with monitoring requirements"
  ]
}
